Table 2.
Bivariate and multivariate analyses on predictors of immunomodulator initiation.
| Bivariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR [95% CI] | p-Value | HR [95% CI] | p-Value | |
| Gender [male] | 0.79 [0.46;1.37] | 0.416 | ||
| Active smoker | 1.32 [0.72;2.42] | 0.361 | ||
| Localisation of disease * | ||||
| Ileum; L1 | 1 | 0.166 | ||
| Colon: L2 | 1.69 [0.80;3.56] | 0.283 | ||
| Ileocolon: L3 | 1.43 [0.74;2.74] | |||
| Behavioura,b | ||||
| Pure inflammatory: B1 | 1 | |||
| Stricturing: B2 | 0.46 [0.21;1.04] | 0.063 | ||
| Penetrating: B3 | 0.81 [0.37;1.74] | 0.585 | ||
| Age at diagnosis [years]a | ||||
| < 16 | 1 | |||
| 17–40 | 1.03 [0.46;2.32] | 0.938 | ||
| > 40 | 1.24 [0.47;3.25] | 0.665 | ||
| Perianal disease | 0.97 [0.56;1.67] | 0.903 | ||
| Previous intestinal resection | 0.85 [0.47;1.53] | 0.591 | ||
| 2nd/3rd/4th line of anti-TNF therapy vs 1st lineb | 1.67 [0.97;2.87] | 0.0622 | 2.00[1.15;3.49] | 0.014 |
| Anti-TNF type[IFX vs ADA] α | 1.92 [1.10;3.35] | 0.0214 | 2.23[1.26;3.95] | 0.006 |
| Concomitant treatment | ||||
| Oral 5-ASA | 1.08 [0.62;1.86] | 0.786 | ||
| Budesonide | 1.41 [0.64;3.14] | 0.396 | ||
| Systemic [oral or intravenous] | 1.52 [0.68;3.36] | 0303 | ||
| steroids | 1.35 [0.73;2.49] | 0.334 | ||
| Indication of anti-TNF initiation | ||||
| Steroid-dependent disease | 1.21 [0.62;2.34] | 0.580 | ||
| Steroid-refractory disease | 0.73 [0.31;1.71] | 0.474 | ||
| Failure of a first anti-TNF therapy | 1.12 [0.63;2.02] | 0.694 | ||
| Flare | 1.03 [0.44;2.42] | 0.938 | ||
5-ASA, 5-aminosalicylic acid; IFX, infliximab; ADA, adalimumab; HR, hazard ratio. 95% CI, 95% confidence interval; TNF, tumour necrosis factor.
aAccording to the Montreal classification.
bFactors introduced in multivariate analysis.